Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (31-40 of 250) with videos related to

Pageof 25
Sort By:
Leukemia & Lymphoma|October 1, 2005
Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patientsMontserrat Batlle, Josep-Maria Ribera, Albert Oriol, et al.
Journal of Medical Internet Research|February 29, 2024
Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in PediatricsHansa Bhargava, Carmela Salomon, Srinivasan Suresh, et al.
Cahiers De Sociologie Et De Demographie Medicales|December 13, 2003
[The White Paper of the health professions of Catalonia]Xavier Pomés, Albert Oriol, Rafael de Oleza, et al.
American Journal of Hematology|June 15, 2007
Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcomeJosé-Tomás Navarro, Evarist Feliu, Javier Grau, et al.
European Journal of Haematology|June 4, 2014
Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myelomaMontserrat Batlle, Mireia Morgades, Susana Vives, et al.
British Journal of Haematology|December 29, 2007
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trialJosep-Maria Ribera, Albert Oriol, Mireia Morgades, et al.
Expert Opinion on Investigational Drugs|September 14, 2020
Melflufen for relapsed and refractory multiple myelomaAlbert Oriol, Alessandra Larocca, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2019
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and SubgroupsRobert Z Orlowski, Philippe Moreau, Ruben Niesvizky, et al.
Leukemia & Lymphoma|March 18, 2024
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT studyAurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, et al.
Leukemia & Lymphoma|February 2, 2012
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experienceAdrian Alegre, Albert Oriol-Rocafiguera, Jose Garcia-Larana, et al.
Pageof 25

Showing results (31-40 of 250) with videos related to

Sort By:
Pageof 25
Leukemia & Lymphoma|October 1, 2005
Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patientsMontserrat Batlle, Josep-Maria Ribera, Albert Oriol, et al.
Journal of Medical Internet Research|February 29, 2024
Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in PediatricsHansa Bhargava, Carmela Salomon, Srinivasan Suresh, et al.
Cahiers De Sociologie Et De Demographie Medicales|December 13, 2003
[The White Paper of the health professions of Catalonia]Xavier Pomés, Albert Oriol, Rafael de Oleza, et al.
American Journal of Hematology|June 15, 2007
Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcomeJosé-Tomás Navarro, Evarist Feliu, Javier Grau, et al.
European Journal of Haematology|June 4, 2014
Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myelomaMontserrat Batlle, Mireia Morgades, Susana Vives, et al.
British Journal of Haematology|December 29, 2007
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trialJosep-Maria Ribera, Albert Oriol, Mireia Morgades, et al.
Expert Opinion on Investigational Drugs|September 14, 2020
Melflufen for relapsed and refractory multiple myelomaAlbert Oriol, Alessandra Larocca, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2019
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and SubgroupsRobert Z Orlowski, Philippe Moreau, Ruben Niesvizky, et al.
Leukemia & Lymphoma|March 18, 2024
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT studyAurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, et al.
Leukemia & Lymphoma|February 2, 2012
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experienceAdrian Alegre, Albert Oriol-Rocafiguera, Jose Garcia-Larana, et al.
Pageof 25